Androgen Deprivation Therapy: Along the Prostate Cancer Continuum
This educational activity will present significant and compelling data on androgen deprivation therapy (ADT) in prostate cancer. Presentations will focus on agents affecting androgen levels in the serum and in tumor cells, particularly the different administration mechanisms and impact on patient outcome. Participants will be challenged to consider the risks and benefits of ADT in various clinical situations, and how to make evidence-based clinical decisions, in order to identify the most appropriate care and patient management. NCCN Guidelines identification of best practices and future directions of clinical issues will be considered.
- 1.50 AMA PRA Category 1 Credit(s)™
- 1.50 Attendance